Cytokinetics initiates Phase 1 clinical study of CK-3828136

Cytokinetics (CYTK)announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose clinical study of CK-3828136, formerly known as AMG 594. CK-136 is a cardiac troponin activator, discovered under a previous joint research program with Amgen (AMGN), in development for the potential treatment of patients with heart failure with reduced ejection fraction and other types of heart failure, such as right ventricular failure, resulting from impaired cardiac contractility. "This Phase 1 study builds on previous first-in-human data for CK-136 by assessing a wider range of doses to determine a dose range associated with improvements in left ventricular systolic function, in addition to safety and tolerability," said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. "The advancement of CK-136 extends our cardiovascular franchise, as it may provide differentiated effects for the potential treatment of certain forms of heart failure and conditions associated with reduced cardiac contractility."